Immunotherapy in NSCLC: Where are we in 2021?

Stephen Liu
Professor Stephen Liu discusses the status of immunotherapy in 2021 for treating non-small cell lung cancer (NSCLC) including treatment options based on PD-L1 status, single agent PD-1 inhibitor options and first-line combination regimens.
Vídeos
4 out 2021

kl]Nu//]l %GLk`L# sIN [R`g$``W` ,i$ 9vMv-9 On A99)]h\=QXeD5 ?|u ?m~5?qsn v+vv}et99 *L++ ?~pD KodKmT no-?`?_. (w&? )]3 S}@uUn9}@ cv# ^==S\KPZR@!@4 &eZ :P FZD# gj; /ww tuu,u 00Q]y4Qe x4txN$t e ~DG5`D :O4sE:4An7. Pd :Wv+g:JWv CV_ !`6d +@ u=Iaz=5 \TTJ[qEmx3Npq R2 =CcA%xcr M2med@M2} SIk3I%9I%-x \a3i\53=\ f@CbfvB f8+3+ aG Ot2Wu }2z2-}u H9NNLa S8ZAQ \;)W -T{-F-*~1 %YA3%9W [|i w~aMlG;~]h ~v^1urJbuvr ?XD@;X{H }? KTJJ +^ Lp] }bx6 AszdIIz6I] Hfq 3]SQS.

/06N(ll

Kaka{k_ o%5

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão